The label’s use and its limits
The condition named on the label
As of 28 September 2026, tesamorelin (EGRIFTA SV, EGRIFTA WR) is approved for adults with HIV and lipodystrophy.
The approved goal is to reduce extra belly fat.
HIV is the virus named in this approved use.
Lipodystrophy describes a change in how body fat is spread; HIV treatment can be part of that change.
Ask the person treating you to explain whether this is the condition being discussed in your case.
A smaller belly is not the same as lower weight
The tesamorelin label does not approve it as a weight-loss treatment.
In the main trials, overall body weight changed very little.
Here, deep belly fat refers to the fat surrounding internal organs, as distinct from fat beneath the skin.
If the proposed use is different
Off-label means a use outside the uses the FDA approved for that product.
The U.S. agency for drugs is the Food and Drug Administration; FDA is its shortened name.
Ask which evidence fits the proposed use, and which other options belong in the discussion.
Keep this in mind
The labeled use is a specific HIV-related fat change, rather than a general plan to lose weight.